GSK PLC Sponsored ADR (NYSE:GSK) Receives $44.13 Consensus Price Target from Brokerages

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have been given a consensus recommendation of “Hold” by the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $44.1250.

GSK has been the topic of several research analyst reports. Wall Street Zen raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. HSBC reiterated a “reduce” rating on shares of GSK in a report on Wednesday, December 10th. Bank of America upgraded GSK from an “underperform” rating to a “neutral” rating in a research note on Tuesday, November 25th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of GSK in a research report on Monday. Finally, Cfra set a $53.00 price target on GSK in a report on Thursday, October 30th.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk purchased 1,470,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $27,930,000.00. Following the purchase, the insider owned 18,245,691 shares of the company’s stock, valued at $346,668,129. This trade represents a 8.76% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Twin Peaks Wealth Advisors LLC acquired a new stake in GSK during the 2nd quarter valued at $25,000. CNB Bank bought a new stake in shares of GSK during the third quarter worth $31,000. SOA Wealth Advisors LLC. increased its stake in shares of GSK by 252.1% in the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 605 shares in the last quarter. CoreFirst Bank & Trust acquired a new stake in shares of GSK in the second quarter valued at $33,000. Finally, MTM Investment Management LLC bought a new position in shares of GSK in the second quarter valued at about $37,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Up 0.2%

Shares of NYSE:GSK opened at $48.96 on Tuesday. GSK has a 1 year low of $31.72 and a 1 year high of $49.44. The company has a debt-to-equity ratio of 0.95, a current ratio of 0.84 and a quick ratio of 0.55. The business’s 50-day moving average is $47.21 and its 200-day moving average is $42.34. The company has a market capitalization of $99.80 billion, a price-to-earnings ratio of 13.83, a P/E/G ratio of 1.33 and a beta of 0.45.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.22. The firm had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $8.21 billion. GSK had a return on equity of 48.64% and a net margin of 17.16%.The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.50 EPS. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Equities research analysts predict that GSK will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 8th. Investors of record on Friday, November 14th will be issued a $0.4171 dividend. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Friday, November 14th. GSK’s dividend payout ratio (DPR) is currently 46.33%.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.